208 related articles for article (PubMed ID: 25740728)
1. Clinical outcome of low-grade central osteosarcoma and role of CDK4 and MDM2 immunohistochemistry as a diagnostic adjunct.
Jeon DG; Koh JS; Cho WH; Song WS; Kong CB; Cho SH; Lee SY; Lee SY
J Orthop Sci; 2015 May; 20(3):529-37. PubMed ID: 25740728
[TBL] [Abstract][Full Text] [Related]
2. MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype.
Yoshida A; Ushiku T; Motoi T; Beppu Y; Fukayama M; Tsuda H; Shibata T
Am J Surg Pathol; 2012 Mar; 36(3):423-31. PubMed ID: 22301501
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical analysis of MDM2 and CDK4 distinguishes low-grade osteosarcoma from benign mimics.
Yoshida A; Ushiku T; Motoi T; Shibata T; Beppu Y; Fukayama M; Tsuda H
Mod Pathol; 2010 Sep; 23(9):1279-88. PubMed ID: 20601938
[TBL] [Abstract][Full Text] [Related]
4. [Value of MDM2, CDK4 and SATB2 immunohistochemistry in histologic diagnosis of low-grade osteosarcoma].
Chen CY; Zhang HZ; Jiang ZM; Zhou J; Chen J; Liu L
Zhonghua Bing Li Xue Za Zhi; 2016 Jun; 45(6):387-92. PubMed ID: 27256046
[TBL] [Abstract][Full Text] [Related]
5. MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone.
Dujardin F; Binh MB; Bouvier C; Gomez-Brouchet A; Larousserie F; Muret Ad; Louis-Brennetot C; Aurias A; Coindre JM; Guillou L; Pedeutour F; Duval H; Collin C; de Pinieux G
Mod Pathol; 2011 May; 24(5):624-37. PubMed ID: 21336260
[TBL] [Abstract][Full Text] [Related]
6. MDM2 and CDK4 expression in periosteal osteosarcoma.
Righi A; Gambarotti M; Benini S; Gamberi G; Cocchi S; Picci P; Bertoni F
Hum Pathol; 2015 Apr; 46(4):549-53. PubMed ID: 25680902
[TBL] [Abstract][Full Text] [Related]
7. The Utility of MDM2 and CDK4 Immunohistochemistry and MDM2 FISH in Craniofacial Osteosarcoma.
Limbach AL; Lingen MW; McElherne J; Mashek H; Fitzpatrick C; Hyjek E; Mostofi R; Cipriani NA
Head Neck Pathol; 2020 Dec; 14(4):889-898. PubMed ID: 32026294
[TBL] [Abstract][Full Text] [Related]
8. Gene amplification and tumor grading in parosteal osteosarcoma.
Chen PC; Yen CC; Hung GY; Pan CC; Chen WM
J Chin Med Assoc; 2019 Dec; 82(12):889-894. PubMed ID: 31634336
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical and FISH analysis of MDM2 and CDK4 in a dedifferentiated extraskeletal osteosarcoma arising in the vastus lateralis muscle: differential diagnosis and diagnostic algorithm.
von Baer A; Ehrhardt A; Baumhoer D; Mayer-Steinacker R; Schultheiss M; Abdul-Nou T; Mentzel T; Fend F; Möller P; Jundt G; Barth TF
Pathol Res Pract; 2014 Oct; 210(10):698-703. PubMed ID: 24974983
[TBL] [Abstract][Full Text] [Related]
10. Parosteal osteosarcoma.
Hang JF; Chen PC
Arch Pathol Lab Med; 2014 May; 138(5):694-9. PubMed ID: 24786129
[TBL] [Abstract][Full Text] [Related]
11. A clinical comparison between dedifferentiated low-grade osteosarcoma and conventional osteosarcoma.
Toki S; Kobayashi E; Yoshida A; Ogura K; Wakai S; Yoshimoto S; Yonemori K; Kawai A
Bone Joint J; 2019 Jun; 101-B(6):745-752. PubMed ID: 31154837
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the 12q15 MDM2 and 12q13-14 CDK4 amplicons and clinical correlations in osteosarcoma.
Mejia-Guerrero S; Quejada M; Gokgoz N; Gill M; Parkes RK; Wunder JS; Andrulis IL
Genes Chromosomes Cancer; 2010 Jun; 49(6):518-25. PubMed ID: 20196171
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors.
Thway K; Flora R; Shah C; Olmos D; Fisher C
Am J Surg Pathol; 2012 Mar; 36(3):462-9. PubMed ID: 22301498
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and treatment of low-grade osteosarcoma: experience with nine cases.
Hayashi K; Tsuchiya H; Yamamoto N; Shirai T; Nishida H; Takeuchi A; Kimura H; Miwa S; Inatani H; Okamoto H; Yamada S; Ikeda H; Sawada-Kitamura S; Nojima T; Ooi A; Otsuka T
Int J Clin Oncol; 2014 Aug; 19(4):731-8. PubMed ID: 23881556
[TBL] [Abstract][Full Text] [Related]
15. A new subtype of high-grade mandibular osteosarcoma with RASAL1/MDM2 amplification.
Guérin M; Thariat J; Ouali M; Bouvier C; Decouvelaere AV; Cassagnau E; Aubert S; Lepreux S; Coindre JM; Valmary-Degano S; Larousserie F; Meilleroux J; Projetti F; Stock N; Galant C; Marie B; Peyrottes I; de Pinieux G; Gomez-Brouchet A
Hum Pathol; 2016 Apr; 50():70-8. PubMed ID: 26997440
[TBL] [Abstract][Full Text] [Related]
16. Giant cell rich osteosarcoma revisited-diagnostic criteria and histopathologic patterns, Ki67, CDK4, and MDM2 expression, changes in response to bisphosphonate and denosumab treatment.
Chow LT
Virchows Arch; 2016 Jun; 468(6):741-55. PubMed ID: 27003154
[TBL] [Abstract][Full Text] [Related]
17. Dedifferentiated liposarcoma and pleomorphic liposarcoma: a comparative study of cytomorphology and MDM2/CDK4 expression on fine-needle aspiration.
Mariño-Enríquez A; Hornick JL; Dal Cin P; Cibas ES; Qian X
Cancer Cytopathol; 2014 Feb; 122(2):128-37. PubMed ID: 24227706
[TBL] [Abstract][Full Text] [Related]
18. Osteosarcoma of the bones of the foot--an easily misdiagnosed malignant tumor.
Biscaglia R; Gasbarrini A; Böhling T; Bacchini P; Bertoni F; Picci P
Mayo Clin Proc; 1998 Sep; 73(9):842-7. PubMed ID: 9737220
[TBL] [Abstract][Full Text] [Related]
19. Conventional and dedifferentiated parosteal osteosarcoma. Diagnosis, treatment, and outcome.
Sheth DS; Yasko AW; Raymond AK; Ayala AG; Carrasco CH; Benjamin RS; Jaffe N; Murray JA
Cancer; 1996 Nov; 78(10):2136-45. PubMed ID: 8918422
[TBL] [Abstract][Full Text] [Related]
20. Role of MDM2, CDK4, BCL2, Parafibromin and Galectin 1 in Differentiating Osteosarcoma from its Benign Fibro-osseous Lesions.
Kaur H; Kala S; Sood A; Mridha AR; Kakkar A; Yadav R; Mishra S; Mishra D
Head Neck Pathol; 2022 Sep; 16(3):728-737. PubMed ID: 35220546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
